Using a three-dimensional clonogenic assay of tumor cells, Sartorius' group determined that ER–, PR–, CD44+ and CK5+ cells should be defined as breast cancer stem cells according to their capacity to produce more differentiated cells, the majority of which are ER+, PR+, CK–[13]. This evidence concerns the gene CD44 and breast cancer.